Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).
Ritu Chaudhary(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Nelusha Amaladas(Eli Lilly (United States)), Aik Choon Tan(Colorado School of Public Health), Keegan P. McCleary‐Sharpe(Moffitt Cancer Center), Feifei Song(Moffitt Cancer Center), Xuefeng Wang(Xuzhou Medical College), Wenjuan Wu(Eli Lilly (United States)), Robbert J.C. Slebos(University of Iowa), Gerald E. Hall(Eli Lilly (United States)), Jude Masannat(Moffitt Cancer Center)
Cited by 1
Related Papers
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
|Cell Metabolism|2012|1.1k